Furthermore, demonstration of MYD88, CD79b or other mutations may offer additional diagnostic value in cases where histology is not definitive, as for example MYD88 is mutated in approximately 85% of PCNSL [33]. This evidence concerns the gene MYD88 and primary central nervous system lymphoma.